This article is more than 5 years old. Information may no longer be current.

NovaBay reports $2.4 million net loss in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBay Pharmaceuticals reported a net loss of $2.4 million, or $0.16 per share, for the third quarter of 2017 compared with a net loss of $3.7 million, or $0.34 per share, for the third quarter of 2016.

Net sales for the quarter rose from $3.4 million to $4.1 million, according to a company press release.

Sales and marketing expenses increased from $2.7 million in 2016’s third quarter to $3.3 million in the third quarter of 2017, which was attributed to an increase in the number of sales representatives and increased sampling and marketing programs.

General and administrative costs were steady at $2.3 million, with research and development expenses increasing from $4,000 to $132,000 for the quarter.